Print

Purpose

To evaluate the effectiveness, patient-reported outcomes (PROs) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS),who transition to cladribine tablets after suboptimal response to any injectable disease-modifying drugs (DMDs) approved in the United States (US) for RMS in a real-world setting.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female participants greater than or equal to (>=)18 years - Signed informed consent - Have diagnosis of RMS including RRMS and aSPMS and satisfy the approved indication for cladribine tablets as per United States Prescribing Information (USPI) - Have time since diagnosis of RMS of at least 12 months - Had received their last previous injectable disease-modifying drug (DMD) for at least 3 months - Have decided to initiate treatment with cladribine tablets during routine clinical care - Meet criteria as per the approved USPI - Have access to a valid e-mail address - In the opinion of the Investigator, experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable DMD treatment

Exclusion Criteria

  • Have been previously treated with cladribine in any dosing form - Transitioning from previous injectable DMD solely for administrative reasons such as relocation - Have comorbid conditions that preclude participation - Have any clinical condition or medical history noted as contraindication on USPI - Are currently participating in an interventional clinical trial - Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during the cladribine treatment period

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Cladribine
  • Drug: Cladribine
    Participants received cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.

Recruiting Locations

More Details

NCT ID
NCT03933215
Status
Completed
Sponsor
EMD Serono Research & Development Institute, Inc.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.